Law Offices of Thomas J. Lamb

  • About Firm
  • Practice Areas
  • Free Case Evaluation
  • Quick Contact Form
  • Frequently Asked Questions
  • Attorney Tom Lamb

FDA Approves Pembrolizumab Plus Chemo for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma

September 19, 2024 By Law Offices of Thomas J. Lamb, P.A.

The FDA has approved [ Keytruda (pembrolizumab) ] plus pemetrexed and platinum chemotherapy in the frontline treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma. Data from the phase 2/3 KEYNOTE-483 study (NCT02784171) showed that [ Keytruda (pembrolizumab) ] plus chemotherapy (n = 222) significantly … [Read more...]

Filed Under: Mesothelioma Tagged With: Keytruda, malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments

Menopause Drug Veozah Liver Problems FDA Warnings

September 15, 2024 By Law Offices of Thomas J. Lamb, P.A.

A Veozah drug label change made on August 31, 2024, added new warnings about liver toxicity and abnormal liver test results, according to a September 12, 2024, Veozah liver problems FDA Drug Safety Communication. According to the “Additional Information for Patients” section of the September 2024 FDA Veozah liver problems warnings document, … [Read more...]

Filed Under: Unsafe Drugs Tagged With: liver damage, liver injury, liver problems, Veozah

Chemotherapy increases CDA expression and sensitizes malignant pleural mesothelioma cells to capecitabine treatment

September 6, 2024 By Law Offices of Thomas J. Lamb, P.A.

Abstract:  The combination of cisplatin and pemetrexed remains the gold standard chemotherapy for malignant pleural mesothelioma (MPM), although resistance and poor response pose a significant challenge. Cytidine deaminase (CDA) is a key enzyme in the nucleotide salvage pathway and is involved in the adaptive stress response to chemotherapy. The … [Read more...]

Filed Under: Asbestos Tagged With: chemotherapy, malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments

Syfovre Claims: Vision Loss and Blindness: Law / Legal

August 27, 2024 By Law Offices of Thomas J. Lamb, P.A.

Syfovre claims for vision loss and blindness involving retinal vasculitis diagnosed after a patient’s first Syfovre injection are being filed as drug injury lawsuits. The basis for these product liability Syfovre lawsuits is the drug company Apellis Pharmaceuticals failed to warn about retinal vasculitis as a side effect until it revised the … [Read more...]

Filed Under: Unsafe Drugs Tagged With: blindness, retinal vasculitis, Syfovre, vision loss

Challenging the Norm: Occurrence of Synchronous Pleural and Peritoneal Mesothelioma in a Female Patient

August 22, 2024 By Law Offices of Thomas J. Lamb, P.A.

Abstract:  Here, we present a unique case involving a female patient in her 40s with synchronous malignant pleural and peritoneal mesothelioma, despite lacking a history of asbestos exposure. The patient’s initial symptoms included dyspnoea, chest pain, cough, fever, appetite loss, and weight loss over a month. Clinical evaluation led to the … [Read more...]

Filed Under: Mesothelioma Tagged With: mesothelioma, peritoneal mesothelioma, pleural mesothelioma

Assessing trends and burden of occupational exposure to asbestos in the United States: a comprehensive analysis from 1990 to 2019

August 8, 2024 By Law Offices of Thomas J. Lamb, P.A.

Background  This study aimed to analyze the trends and burden of occupational exposure to asbestos in the United States (U.S.) from 1990 to 2019, focusing on mortality rates, geographic distribution, age and sex patterns, and causes of death. Methods  Data on the number of deaths attributable to occupational exposure to asbestos were collected … [Read more...]

Filed Under: Asbestos Tagged With: asbestos, asbestos exposure

Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma—Protocol of the Immuno-MESODEC study

July 26, 2024 By Law Offices of Thomas J. Lamb, P.A.

Abstract Malignant pleural mesothelioma (MPM) is an aggressive cancer with a very poor prognosis. Recently, immune checkpoint inhibition (ICI) has taken center stage in the currently ongoing revolution that is changing standard-of-care treatment for several malignancies, including MPM. As multiple arguments and accumulating lines of evidence are … [Read more...]

Filed Under: Mesothelioma Tagged With: malignant pleural mesothelioma (MPM), mesothelioma treatments

Semaglutide Blood Clots Side Effects: Ozempic, Rybelsus, and Wegovy

July 23, 2024 By Law Offices of Thomas J. Lamb, P.A.

We have been receiving reports of people diagnosed with deep vein thrombosis (DVT), pulmonary embolism (PE), portal vein thrombosis (PVT), and ischemic stroke as possible semaglutide blood clots side effects. Ozempic, Rybelsus, and Wegovy are drugs with semaglutide as their active ingredient. Semaglutide Blood Clots Side Effects: DVT and Pulmonary … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Deep Vein Thrombosis (DVT), Ischemic Stroke, Ozempic, Portal Vein Thrombosis (PVT), Pulmonary Embolism (PE), Rybelsus, Wegovy

Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial

July 18, 2024 By Law Offices of Thomas J. Lamb, P.A.

Background:  Extended pleurectomy decortication for complete macroscopic resection for pleural mesothelioma has never been evaluated in a randomised trial. The aim of this study was to compare outcomes after extended pleurectomy decortication plus chemotherapy versus chemotherapy alone. Methods:  MARS 2 was a phase 3, national, multicentre, … [Read more...]

Filed Under: Mesothelioma Tagged With: chemotherapy, decortication, mesothelioma, mesothelioma treatments, pleural mesothelioma, pleurectomy

Ozempic Side Effects Include Eye Problems With Possible Vision Loss

July 18, 2024 By Law Offices of Thomas J. Lamb, P.A.

In July 2024 we learned from a recent medical study that Ozempic side effects include eye problems with possible vision loss. More specifically, nonarteritic anterior ischemic optic neuropathy (NAION) has been linked to semaglutide — the active ingredient in Ozempic as well as Wegovy and Rybelsus. As such, this finding about the new NAION Ozempic … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), Ozempic, Rybelsus, vision loss, Wegovy

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 22
  • Next Page »

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • Drug Injury Lawsuits
  • Breast Implant Cancer Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

DrugInjuryLaw.com

DrugInjuryWatch.com

Asbestos-Mesothelioma.com

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Disclaimer and Copyright Notices
  • Sitemap

Copyright © 2025 · Law Offices of Thomas J. Lamb, P.A.